These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 20062994)

  • 1. Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development.
    Soto E; Staab A; Tillmann C; Trommeshauser D; Fritsch H; Munzert G; Trocóniz IF
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):785-95. PubMed ID: 20062994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
    Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
    Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.
    Soto E; Staab A; Doege C; Freiwald M; Munzert G; Trocóniz IF
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1517-27. PubMed ID: 21516508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.
    Mross K; Frost A; Steinbild S; Hedbom S; Rentschler J; Kaiser R; Rouyrre N; Trommeshauser D; Hoesl CE; Munzert G
    J Clin Oncol; 2008 Dec; 26(34):5511-7. PubMed ID: 18955456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
    Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
    Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies.
    Olmos D; Barker D; Sharma R; Brunetto AT; Yap TA; Taegtmeyer AB; Barriuso J; Medani H; Degenhardt YY; Allred AJ; Smith DA; Murray SC; Lampkin TA; Dar MM; Wilson R; de Bono JS; Blagden SP
    Clin Cancer Res; 2011 May; 17(10):3420-30. PubMed ID: 21459796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed.
    Soto E; Staab A; Freiwald M; Munzert G; Fritsch H; Döge C; Trocóniz IF
    Clin Pharmacol Ther; 2010 Nov; 88(5):660-7. PubMed ID: 20927084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
    Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
    Lin CC; Su WC; Yen CJ; Hsu CH; Su WP; Yeh KH; Lu YS; Cheng AL; Huang DC; Fritsch H; Voss F; Taube T; Yang JC
    Br J Cancer; 2014 May; 110(10):2434-40. PubMed ID: 24755882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia.
    Müller-Tidow C; Bug G; Lübbert M; Krämer A; Krauter J; Valent P; Nachbaur D; Berdel WE; Ottmann OG; Fritsch H; Munzert G; Garin-Chesa P; Fleischer F; Taube T; Döhner H
    Br J Haematol; 2013 Oct; 163(2):214-22. PubMed ID: 24033250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours.
    Schöffski P; Awada A; Dumez H; Gil T; Bartholomeus S; Wolter P; Taton M; Fritsch H; Glomb P; Munzert G
    Eur J Cancer; 2012 Jan; 48(2):179-86. PubMed ID: 22119200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.
    Kobayashi Y; Yamauchi T; Kiyoi H; Sakura T; Hata T; Ando K; Watabe A; Harada A; Taube T; Miyazaki Y; Naoe T
    Cancer Sci; 2015 Nov; 106(11):1590-5. PubMed ID: 26471242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
    Schöffski P
    Oncologist; 2009 Jun; 14(6):559-70. PubMed ID: 19474163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism-based models for topotecan-induced neutropenia.
    Léger F; Loos WJ; Bugat R; Mathijssen RH; Goffinet M; Verweij J; Sparreboom A; Chatelut E
    Clin Pharmacol Ther; 2004 Dec; 76(6):567-78. PubMed ID: 15592328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
    Fetterly GJ; Grasela TH; Sherman JW; Dul JL; Grahn A; Lecomte D; Fiedler-Kelly J; Damjanov N; Fishman M; Kane MP; Rubin EH; Tan AR
    Clin Cancer Res; 2008 Sep; 14(18):5856-63. PubMed ID: 18794097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors.
    Bowers S; Truong AP; Ye M; Aubele DL; Sealy JM; Neitz RJ; Hom RK; Chan W; Dappen MS; Galemmo RA; Konradi AW; Sham HL; Zhu YL; Beroza P; Tonn G; Zhang H; Hoffman J; Motter R; Fauss D; Tanaka P; Bova MP; Ren Z; Tam D; Ruslim L; Baker J; Pandya D; Diep L; Fitzgerald K; Artis DR; Anderson JP; Bergeron M
    Bioorg Med Chem Lett; 2013 May; 23(9):2743-9. PubMed ID: 23522834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
    Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
    Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
    Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM
    Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.